started · updated
AASLD Liver Meeting highlights breakthroughs in Hepatitis B and MASH research
The American Association for the Study of Liver Diseases (AASLD) has announced 42 late-breaking research abstracts for its 2026 meeting in Denver. The program focuses heavily on Hepatitis B and metabolic dysfunction-associated steatohepatitis (MASH), which together account for more than half of the selections.
Research presented includes late-stage clinical trials, early-phase RNA editing studies, and advancements in blood-based diagnostics. Notably, the program highlights the recent FDA approval of a hepatitis B drug from GSK. Other featured studies involve Phase 3 trials for primary biliary cholangitis, chronic hepatitis D, and compensated cirrhosis.
In diagnostic developments, researchers introduced LiquidTransformer, an experimental blood test from Hepta. The test, which analyzes circulating DNA, reportedly matches the accuracy of magnetic resonance elastography (MRE) in determining the extent of chronic liver disease. This technology can distinguish between different forms of steatotic liver disease, including MASLD, ALD, and MetALD, and has been used to monitor molecular changes in patients receiving semaglutide.
Entities
American Association for the Study of Liver Diseases · Denver · GSK · Hepta · Madrigal Pharmaceuticals